![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
| Item Type: | Article |
|---|---|
| Title: | Management of busulfan-induced lung injury in pediatric patients with high-risk neuroblastoma |
| Creators Name: | Castelli, S., Thorwarth, A., van Schewick, C., Wendt, A., Astrahantseff, K., Szymansky, A., Lodrini, M., Veldhoen, S., Gratopp, A., Mall, M.A., Eggert, A. and Deubzer, H.E. |
| Abstract: | BACKGROUND/OBJECTIVES: Integrating the cytotoxic drug busulfan into a high-dose chemotherapy regimen prior to autologous hematopoietic stem cell rescue in patients with high-risk neuroblastoma has improved the survival of children battling this deadly disease. Busulfan-induced toxicities can, however, be severe. Here, we describe the diagnosis and successful treatment of acute pulmonary injury by total-body-weight-adjusted busulfan therapy in two children with high-risk neuroblastoma. CASE SERIES: Patient 1 developed life-threatening biphasic acute respiratory failure on days +60 and +100 after busulfan therapy, requiring intubation and invasive mechanical ventilation. Despite intensive anti-inflammatory and immunomodulatory therapy, including systemic corticosteroids, topical inhalation regimens, azithromycin, nintedanib and extracorporal photopheresis, patient 1 required extended intensive care measures and non-invasive respiratory support for a total of 20 months. High-resolution computed tomography showed diffuse intra-alveolar and interstitial patterns. Patient 2 developed partial respiratory failure with insufficient oxygen saturation and dyspnea on day +52 after busulfan therapy. Symptoms were resolved after 6 months of systemic corticosteroids, topical inhalation regimens and azithromycin. High-resolution computed tomography showed atypical pneumonic changes with ground-glass opacities. While both patients fully recovered without evidence of pulmonary fibrosis, cancer therapy had to be paused and then modified until full recovery from busulfan-induced lung injury. CONLCUSIONS: Busulfan-induced lung injury requires prompt diagnosis and intervention. Symptoms and signs are nonspecific and difficult to differentiate from other causes. Therapeutic busulfan drug level monitoring and the identification of patients at risk for drug overdosing through promoter polymorphisms in the glutathione S-transferase alpha 1 gene encoding the main enzyme in busulfan metabolism are expected to reduce the risk of busulfan-induced toxicities. |
| Keywords: | Busulfan, Busulfan-Induced Lung Injury, High-Dose Chemotherapy, Neuroblastoma, Pediatric Cancer, Pharmacogenomics, Restrictive Lung Disease, Therapeutic Drug Monitoring |
| Source: | Journal of Clinical Medicine |
| ISSN: | 2077-0383 |
| Publisher: | MDPI |
| Volume: | 13 |
| Number: | 19 |
| Page Range: | 5995 |
| Date: | 8 October 2024 |
| Official Publication: | https://doi.org/10.3390/jcm13195995 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
